Acumen Pharmaceuticals

Company snapshot

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Acumen Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Acumen Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   ACU193-201 — Phase 2

2. Jun 5, 2026 Clinical update

   sabirnetug — Phase 2

3. Jun 5, 2026 Clinical update

   sabirnetug (ACU193) — Phase 1

4. Jun 5, 2026 Clinical update

   ACU193 — Phase 1

5. Apr 26, 2016 Patent grant

   Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

View all clinical trial activity →

• What is Acumen Pharmaceuticals?

  Acumen Pharmaceuticals is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker ABOS. Primary therapeutic focus areas include Alzheimer Disease. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 6 patent record(s) to this entity from

• Is Acumen Pharmaceuticals publicly traded?

  Yes. Acumen Pharmaceuticals is listed with ticker ABOS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Acumen Pharmaceuticals develop or market?

  We link 9 drug profile(s) where Acumen Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/acumen-pharmaceuticals#company-drugs.

• What are the latest developments for Acumen Pharmaceuticals?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Acumen Pharmaceuticals focus on?

  Acumen Pharmaceuticals focuses on Alzheimer Disease based on our analysis of their pipeline programs and drug development activities.